Sydney-based Pharmaxis(ASX:PXS) has announced it is progressing the development of an oral anti‐fibrotic Lysyl Oxidase (LOX) inhibitor for the treatment of myelofibrosis and pancreatic cancer. …
Latest Video
New Stories
-
Greg Hunt could up the ante with speculated appointment
November 15, 2019 - - Latest News -
Malaria researcher wins GSK Award for Research Excellence
November 15, 2019 - - Latest News -
Australian company doses first patient in 'tumour agnostic' study
November 15, 2019 - - Latest News -
Stakeholders leave meeting none-the-wiser on negotiation progress
November 15, 2019 - - Latest News -
PHARMAC switch now blamed for three deaths
November 14, 2019 - - Latest News -
7CPA deal unlikely in 2019
November 14, 2019 - - Latest News -
New report highlights system challenge for Alzheimer's treatment
November 14, 2019 - - Latest News